Intravenous administration of 4F-PCC 50 , 25 , or 10 IU/kg following administration of edoxaban ( 60 mg ) dose-dependently reversed edoxaban 's effects on bleeding duration and endogenous thrombin potential , with complete reversal at 50 IU/kg .